Last update Oct. 11, 2017

2′-(5-Nitrofurfurylidene)-4-hydroxybenzohydrazide

Compatible

Safe substance and/or breastfeeding is the best option.

An antibacterial with very few bibliographical references which is used with little evidence of its efficacy (N.A.L. Prescrire 2004 and 1999) in the treatment of acute gastroenteritis of bacterial origin.

Since the last update we have not found published data about its excretion in breast milk.

It has a very low oral bioavailability, due to low or zero intestinal absorption (Armstrong 2015), making it unlikely its would pass into breast milk.

Its low oral bioavailability would also further complicate its passing into the infant’s plasma via ingested breast milk, except in premature babies and in the immediate neonatal period during which there may be greater intestinal permeability.

Alternatives

We do not have alternatives for 2′-(5-Nitrofurfurylidene)-4-hydroxybenzohydrazide since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

2′-(5-Nitrofurfurylidene)-4-hydroxybenzohydrazide is Nifuroxazide in Chemical name.

Is written in other languages:

Group

2′-(5-Nitrofurfurylidene)-4-hydroxybenzohydrazide belongs to this group or family:

Tradenames

Main tradenames from several countries containing 2′-(5-Nitrofurfurylidene)-4-hydroxybenzohydrazide in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. Baja - Poor %
Molecular weight 275 daltons

References

  1. Armstrong. Nifuroxazida (ESKAPAR). Ficha técnica. 2005 Full text (in our servers)
  2. [No authors listed] Nifuroxazide: licence modification. New restrictions in children. Prescrire Int. 2004 Abstract
  3. [No authors listed] Nifuroxazide in acute diarrhoea: OTC preparation. Irrational. Prescrire Int. 1999 Abstract

Total visits

1,788

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM